If "real world" treatments are to involve multiple infusions of injections of MPCs, phase 3 studies MUST incorporate this into their design (e.g. 4 arm study with 1 infusion placebo or MPC; multiple temporally-spaced infusions of placebo or MPC). They cannot do a single-treatment study which shows modest results then extrapolate that to persuade clinicians to prescribe multiple treatments outwith trial conditions.
I haven't seen any of Mesoblast's Ph3 study protocols so can't comment further, does anyone have a link?
Also, I would not refer to the phase 2 results as "jaw-dropping". They are positive and suggest safety and efficacy, but I would reiterate that there is still a long way to go!
credible critique or not?, page-10
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.21 |
Change
-0.050(3.98%) |
Mkt cap ! $1.367B | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.23 | $1.20 | $2.713M | 2.247M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 48847 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.21 | 56077 | 13 |
View Market Depth
| Last trade - 11.17am 25/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |